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Management of chemotherapy-associated febrile neutropenia
D Cameron*,1
1NCRN Coordinating Centre, University of Leeds, MacMillan Wing, Fairbairn House, 71–75 Clarendon Road, Leeds LS2 9PH, UK
The development of febrile neutropenia during a course of chemotherapy is not only a life-threatening complication, it can also lead
to a decision to reduce chemotherapy intensity in subsequent treatment cycles, thus putting patient outcomes at risk. Although there
are strategies available for the primary prevention of febrile neutropenia, these are not widely used in the UK management of breast
cancer. It is, therefore, paramount to have a well thought out and rigorously implemented care protocol for febrile neutropenia,
involving patients, family/carers and health-care professionals in both primary and secondary care, to ensure early detection and
effective management.
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Febrile neutropenia is a serious side effect of many forms of
chemotherapy (Aapro et al, 2006). It is associated with significant
morbidity and mortality, and can lead to a decision to reduce or
delay subsequent chemotherapy doses, which can have implica-
tions for treatment efficacy (Aapro et al, 2006). The risk of
developing febrile neutropenia depends on the degree and
duration of chemotherapy-induced neutropenia and on a number
of patient factors, including age, comorbidity and serum albumin
levels (Bodey et al, 1966; Meza et al, 2002; Lyman et al, 2005; Aapro
et al, 2006).
The definition of febrile neutropenia, together with its possible
consequences, is discussed elsewhere in this supplement (Krell and
Jones, 2009). Similarly, elsewhere in this supplement, Kelly and
Wheatley address the important question of how, and when,
primary prevention is appropriate for patients with breast cancer
(Kelly and Wheatley, 2009). However, primary prevention through
the use of granulocyte colony-stimulating factors (G-CSF) is not
commonly recommended in protocols for the management of
breast cancer in the United Kingdom, and a significant proportion
of patients undergoing chemotherapy for breast cancer go on to
develop febrile neutropenia (Leonard et al, 2003), making its
management an important consideration. This is particularly so in
some of the taxane-based adjuvant chemotherapy regimens
(Martin et al, 2005; Smith et al, 2006).
IMPORTANCE OF LOCAL PROTOCOLS
Effective local strategies for diagnosing and managing febrile
neutropenia are essential components of breast cancer services
(NCEPOD, 2008). Unfortunately, such strategies are prey to several
potential stumbling blocks, as summarised in Table 1.
A survey reported in 2008 by the National Confidential Enquiry
into Patient Outcome and Death (NCEPOD), looking at the care
delivered to patients who died within 30 days of chemotherapy,
identified several common failings in the management of febrile
neutropenia (NCEPOD, 2008). Serious shortcomings were evident
in patient education/awareness, health-care professional educa-
tion/awareness and the availability and implementation of clear
protocols for patient assessment, treatment and hospital admission
(NCEPOD, 2008).
The NCEPOD report emphasises the need for rapid referral and
assessment structures for potential febrile neutropenia to be in
place, and for accessibility to all patients at risk. The models used
may vary from centre to centre. However, the important feature is
that all concerned, from the patient and their relatives, to primary
and secondary care staff, are aware of the agreed procedure and
management guidelines.
WHAT SHOULD PATIENTS LOOK OUT FOR?
The first challenge in the diagnosis of febrile neutropenia is to
make sure that patients will recognise signs suggesting that they
are seriously ill – and take the necessary action.
It is essential to inform all patients receiving chemotherapy for
breast cancer about the risk of febrile neutropenia, and to explain
what to look out for, before they start their treatment. Typical
signs include a temperature higher than 37.51C, flu-like symptoms,
mouth ulcers or a sore mouth that prevents eating (Malik
et al, 2001). Less commonly with many of the regimens used in
the treatment of breast cancer, patients may also have uncontrolled
diarrhoea/vomiting, and uncontrolled nose bleeds or bleeding
from the gums. Patients should also be made aware that they might
not feel hot – indeed, those most at risk sometimes feel cold, or
may merely describe systemic malaise/pain (Malik et al, 2001).
It is important to indicate to patients and carers, depending on
the specific chemotherapy regimen, the days in the treatment cycle
when neutrophil counts are likely to be at their lowest and the risk
of febrile neutropenia is considered to be greatest. For example,
many regimens have nadirs between days 10 and 14 (Hall et al,
2005), but docetaxel monotherapy tends to result in severe
neutropenia several days earlier, on days 5–9 (Chan et al, 1999).
However, timing should not be overemphasised, as the side effect
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important when a patient is switching from anthracycline to
docetaxel (as would be the case on the FEC-T (5-fluoroura-
cilþ epirubicinþ cyclophosphamide followed by docetaxel) regi-
men often used in clinical practice), when it may be helpful to draw
attention to the comparatively early neutrophil nadir associated
with the latter drug and the potential, therefore, for cumulative
risk (Head et al, 2008).
WHO SHOULD PATIENTS CALL, AND WHEN?
The next challenge in the diagnosis and management of febrile
neutropenia is to make sure the patient’s symptoms are commu-
nicated appropriately and effectively, so that they enter the
necessary care pathway (Figure 1).
One major pitfall is the reticence that many patients have
towards ‘troubling the busy doctor’, particularly outside of surgery
hours, and it is important to stress the need to seek help as soon as
signs of possible febrile neutropenia develop.
Some chemotherapy teams, particularly those managing leukae-
mia, which carries an especially high risk of treatment-induced
infection (Gillis et al, 1996), instruct patients to make direct
contact with their chemotherapy service in the event of symptoms
suggesting febrile neutropenia. However, equivalent advice for
patients with solid tumours could swamp oncology staff in some
services, and the approach taken varies across the country. For
example, some teams ask patients to make direct contact with the
chemotherapy service within clinic hours, and/or an on-call senior
nurse outside of the normal working weekday; some instruct
patients to contact emergency primary care services, whatever the
day or time. The latter strategy carries the risk that the busy on-call
GP will not get the full picture from the patient and will fail to
recognise the severity of the risk, which also applies to patients
visiting A&E with symptoms of febrile neutropenia.
The potential time lag from presentation to treatment bears a
serious risk – as antibiotics should be administered within 60min
of any signs and symptoms of febrile neutropenia developing.
Lack of communication between the treating physician at A&E
and the patient’s oncology department can lead to insufficient
knowledge of the patient’s case and history; this issue could
be resolved by implementing communication protocols that
ensure that the patient’s oncology team is fully notified of
any treatment that their patient has received. In light of these
concerns, several chemotherapy services offer patients a back-up
contact point if they feel unhappy with the input from community
services.
WHAT SHOULD BE ASSESSED INITIALLY?
The initial assessment is clinical, beginning with the patient’s vital
signs, including the consciousness level, respiration, circulation
and temperature.
Any chemotherapy patient who is clinically septic should be
regarded as a medical emergency. If the assessment is taking place
in primary care, it is essential for the GP to be aware that the
patient is undergoing chemotherapy, and to have a low threshold
for referral to hospital. To optimise communication at this stage,
many chemotherapy services give patients an information sheet,
outlining details of their chemotherapy regimen, advice on the
signs of febrile neutropenia and guidance on when and where
patients who may need treatment should be referred.
WHERE SHOULD THE PATIENT BE REFERRED?
A patient on conventional chemotherapy who is well and afebrile
does not need to be referred to hospital. However, if a patient on
chemotherapy is febrile (e.g., over 381C, or over 37.51C for at least
1 h), or subthermic and at risk of being neutropenic, it is important
to follow locally agreed management guidelines.
It is essential that all parties likely to be involved in the care of
patients receiving chemotherapy – including health-care profes-
sionals in the community – are aware of the local guidelines and
follow them. For example, many chemotherapy services clearly
stipulate that patients should not be referred to A&E, but directly
to the haematology or oncology inpatient ward/team, depending
on the underlying cancer. However, even when such a policy is in
place, it remains paramount to keep the local A&E staff informed
and educated about management policies for patients who may
have chemotherapy-induced febrile neutropenia. A&E depart-
ments may well receive these patients, despite local policy. For
example, some patients will self-refer, and an individual who is
very septic and/or unconscious may be brought to the department
directly after a 999 call-out.
Referral to A&E presents a particular challenge to the optimum
management of such patients. Compared with other people
arriving in the department, a profoundly neutropenic and septic
patient may look ‘well’, and there is a risk that their condition may
deteriorate when they are left to await their turn in triage.
In light of this risk, and in line with the NCEPOD report on
deaths after chemotherapy, all A&E departments should be aware
of the local policy on the management of neutropenic sepsis, and
copies of the policy should be easily available to all health
professionals on duty (NCEPOD, 2008). Moreover, there should be
Table 1 Potential pitfalls (and solutions) in the diagnosis and management of febrile neutropenia in women undergoing chemotherapy for breast cancer
(NCEPOD, 2008; NCAG, 2009)
Potential pitfall Solution/s
Patient unaware of the significance of early symptoms of febrile neutropenia Patient education
Clear take-home information
Patient reluctant to seek help out of hours Patient education
Clear take-home information
Patient contacts GP, who fails to recognise the magnitude of the risk Information and liaison across primary and secondary care
Patient-held information card to guide GP
Back-up contact point for patients who are not sure their GP has
responded appropriately
Patient referred (or self-referred) to A&E, and not prioritised in triage Provision of education and information for A&E staff
Copy of local protocol available in every A&E department
Access to staff who are familiar with the policy
Appropriate antibiotics available in A&E
Delays in symptom assessment and treatment during transfer to radiology Patient accompanied and monitored when taken off the ward
Delayed delivery of antibiotic therapy when awaiting investigation results Empirical use of antibiotic therapy
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ready access to staff who are familiar with the neutropenic sepsis
policy, and antibiotics specified by the policy should be kept in the
A&E department.
Importantly, the oncology team must be made aware of any
patient on chemotherapy reporting and receiving treatment for
neutropenic sepsis at A&E, as future cycles of chemotherapy may
need to be delayed, dose adjusted or supported with prophylactic
G-CSF or antibiotics in the interests of patient safety.
HOW SHOULD THE PATIENT BE MANAGED?
On referral to hospital, rapid treatment of all patients with febrile
neutropenia is paramount to prevent life-threatening deterioration
of the minority who have a serious infection.
It is essential to have an agreed local policy on the standard
investigations and interventions. These are not decisions that
should be left in the hands of the junior doctor on duty (NCEPOD,
2008).
Full examination should include the mouth and perineum,
and the basic blood tests required include full blood count,
C-reactive protein, urea and electrolytes, creatinine, liver
function, glucose, calcium and albumin (Malik et al, 2001; Hughes
et al, 2002). Peripheral and, where appropriate, central venous
blood cultures should be taken and examined for fungi and
bacteria. Additional tests can be ordered as clinically appropriate,
with a low threshold for stool culture (Malik et al, 2001; Hughes
et al, 2002).
Most departments will have a policy for swabs, clotted serum
for antibody titres, urinalysis and chest X-ray. Note, however,
that the time required to organise and obtain an X-ray should
not be allowed to delay urgent blood tests and the commencement
of treatment. Indeed, any high-risk patient who needs to be taken
off the ward should be escorted to allow continual clinical
monitoring.
It is advisable to establish intravenous access at an early stage in
case the patient subsequently develops shock (Malik et al, 2001). It
is also sensible to commence intravenous fluids (unless contra-
indicated) when the full clinical picture is being assessed.
One key question is whether to commence antibiotics before the
full blood count and biochemistry are known. This will depend on
local practice and the severity of the clinical picture. For example,
although local guidelines recommend the use of aminoglycosides,
it may be prudent to wait until the patient’s renal function is
known. However, the NCEPOD report clearly emphasises the
importance of rapid intervention if patients satisfy the criteria for
febrile neutropenia, and recommends the empirical use of
intravenous antibiotic therapy while the bacteriology results are
awaited (NCEPOD, 2008).
ADMIT OR NOT?
It is a widespread practice to admit all patients with a diagnosis of
febrile neutropenia, usually to a ward area where there is expertise
in the management of the condition. Some district general
hospitals admit such patients under the general medical team,
but even some small hospitals have a designated area for the
management of febrile neutropenia.
However, there is at least one randomised study that has shown
no significant difference in mortality or morbidity between
patients managed in hospital and those managed as outpatients,
as long as a number of key criteria are met (Malik et al, 1995).
These criteria include the lack of any significant systemic upset or
comorbidity, and the use of daily monitoring (Moores, 2007). Few
hospitals in the United Kingdom have implemented an outpatient
approach to the management of febrile neutropenia (Ziglam et al,
2007), as such a policy would require changes in service delivery,
including the provision of a demarcated day bed area for rapid
assessment of new patients, a robust 24-h on-call system, a clear
Ideal care pathway
Alternative care pathways,
often resulting in suboptimal
management of febrile 
neutropenia
Patient feels ‘unwell’ 
(temperature, fever, flu-like symptoms, sore throat, shivering) 
Patient sent to designated 
place–e.g. oncology day 
unit, acute oncology 
assessment unit
Patient told to rest/
given oral antibiotics
Patient contacts
GP or rings 999/
NHS direct
Patient calls 
specified number
Patient goes to/sent to
local hospital/alternative
hospital with capability
out-of-hours
Patient sent to
accident and 
emergency
Patient does 
nothing
Patient receives 
intravenous antibiotics 
within 60 min
Patient receives 
protocol-specified
antibiotics within
60 min
Patient told to rest/
given non-standard 
antibiotics
Patient sent to hospital
where they received their
chemotherapy or some
other designated 
hospital for management 
of chemotherapy-related 
infection complications
Figure 1 Gold standard care pathway for patient with febrile neutropenia.
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mechanism for admitting patients who deteriorate and dedicated
staff for the daily review of current neutropenic patients and
suspected cases. Clearly, the health-care professional who makes
the initial assessment would need to be competent to decide who
does or does not need to be admitted.
WHICH TYPE(S) OF ANTIBIOTIC?
The choice of which antibiotic(s) to use needs to be established as
a local policy, in consultation with the clinical teams managing
patients on chemotherapy, and the microbiologists who monitor
local patterns of infection and resistance.
First line
A combination of an aminoglycoside and a broad-spectrum
antibiotic was established as the standard first-line therapy of
febrile neutropenia in a series of randomised clinical trials from
the European Organization for Research and Treatment of Cancer
(Cometta and Glauser, 1996). However, there are data suggesting
that broad-spectrum antibiotic monotherapy can be effective,
particularly in low-risk patients (usually defined as those without
comorbidity, organ dysfunction and localised or deep-seated sites
of infection, who are normotensive and whose neutropenia is
expected to be brief) (Karthaus et al, 1998; Chamorey et al, 2004;
NWCN, 2007). Similarly, there are at least two randomised trials
that have shown that combination oral antibiotics are at least as
effective as standard intravenous combinations (Freifeld et al,
1999; Kern et al, 1999).
In some protocols, the presence of an indwelling device, such as
a Hickman line, influences the choice of first-line antibiotic
therapy, as such a device can change the distribution of likely
causative organisms (Boland et al, 2003).
Second line
Most policies suggest changing to a second-line antibiotic if the
patient remains febrile for 48 h, or earlier if the patient deteriorates
or positive blood cultures are obtained (Hoy, 2009). As with first-
line antibiotics, it is important that agreed local policies are
followed, along with expert clinical judgement.
IS COLONY-STIMULATING THERAPY NEEDED?
Again, local guidelines should set out the indications for using
G-CSF during treatment of neutropenia.
Uncomplicated, short-duration neutropenia should not need
routine G-CSF support, even if the patient is febrile. However,
many local policies advocate the treatment if the patient is
clinically septic and/or hypotensive, expected to have neutropenia
of long duration (as with certain chemotherapeutic regimens for
haematological diseases), or has organ dysfunction (NWCN, 2007).
It is not good practice to wait and see if the patient struggles to
recover from the neutropenic event; it is far better to identify those
patients at greater risk and intervene early, even given the current
absence of randomised data showing that this approach improves
survival.
SHOULD PATIENTS BE TRANSFERRED TO
INTENSIVE CARE?
If a patient with a neutropenic event is considered sufficiently ill to
warrant intensive care, then the transfer is almost always
appropriate. One exception might be the patient who is being
treated in the palliative setting who has clear evidence of refractory
disease with little possibility of effective alternative systemic
therapy. However, just because a patient does not have a curable
disease, intensive care should not be ruled out. Ideally,
such difficult decisions will be rendered unnecessary through
previous discussions with the patient about their end-of-life care
and by swift, appropriate management of febrile neutropenia.
WHAT ARE THE IMPLICATIONS FOR SUBSEQUENT
CHEMOTHERAPY?
The implications of a neutropenic event for further chemotherapy
depend very much on the treatment intent. Where the treatment is
palliative, there is an important balance to be struck between, on
the one hand, toxicity and loss of quality of life, and on the other,
tumour shrinkage, life prolongation and improved quality of life.
In most cases, this will mean that it is in the patient’s best interest
to have a delay in the next cycle of chemotherapy to allow time for
a full recovery, and then a modification of the dose or regimen to
reduce the risk of further neutropenic fever/sepsis. The use of
secondary prophylactic G-CSF is an alternative, but one that is not
widely used in palliative care in the United Kingdom.
In contrast, where the treatment is curative – adjuvant or
neo-adjuvant – many clinicians would argue that it is important
to maintain the chemotherapy dose and schedule. In this
situation, although a delay may be needed to allow for reasonable
recovery of the neutrophil levels, every effort should be made to
get the subsequent cycles of chemotherapy completed on time
and at the full dose, which may require secondary prophylaxis with
G-CSF.
The decision whether or not to reduce or delay the next adjuvant
chemotherapy dose is rendered more complex if the patient has
suffered a genuinely life-threatening episode of neutropenia. A
neutropenic death during adjuvant chemotherapy is a tragedy that
should be avoided wherever possible – hence the potential
argument for dose delay or reduction. However, it is also
important to ensure effective treatment of the cancer, or the
patient may survive febrile neutropenia only to die later from
metastatic disease. The risk of neutropenia in subsequent cycles is
reduced by the use of primary prophylaxis of febrile neutropenia,
and this should be considered where indicated by the risk
associated with the regimen and individual patient factors
(Gafter-Gvili et al, 2005; Aapro et al, 2006; Smith et al, 2006;
Kelly and Wheatley, 2009).
WHAT CAN WE LEARN FROM PRACTICE?
Audit of the circumstances surrounding cases of febrile neutro-
penia, particularly those resulting in death or severe morbidity,
highlights good and poor practice, and provides pointers for
improving care for patients undergoing chemotherapy.
The NCEPOD survey found that only about half of the hospitals
conducted audits of neutropenic sepsis, and that only 16% of the
deaths within 30 days of systemic anti-cancer therapy were
discussed at morbidity and mortality meetings (NCEPOD, 2008).
The report recommends a formal discussion of all such deaths, a
regular audit of all cases of neutropenic sepsis following
chemotherapy, and the inclusion of protected time for audit in
consultants’ job plans (NCEPOD, 2008).
CONCLUSION
Febrile neutropenia is a common and serious complication of
chemotherapy, and hence it is important to have locally agreed
protocols that are well publicised across primary and secondary
care, and subject to regular review. Regular audit, in-depth
discussion of deaths and serious morbidity associated with febrile
neutropenia, and active liaison with health-care professionals in
the primary and secondary care services are important to ensure
Management of febrile neutropenia
D Cameron
S21
British Journal of Cancer (2009) 101(S1), S18 – S22& 2009 Cancer Research UK
that all patients with possible febrile neutropenia are assessed and
treated appropriately, consistently, safely and rapidly.
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